What is Aurinia Pharmaceuticals's D&A?

Aurinia Pharmaceuticals (AUPH) reported D&A of $4.82M in Q1 2026.

How has Aurinia Pharmaceuticals's D&A changed year-over-year?

Aurinia Pharmaceuticals's D&A decreased by 0.8% year-over-year, from $4.86M to $4.82M.

What is the long-term trend for Aurinia Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's D&A has grown at a 80.8% compound annual growth rate (CAGR), from $1.82M to $19.45M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Aurinia Pharmaceuticals AUPH D&A

D&A at other companies

Rogers CorporationROG

$13.4M+6.3%

Vera TherapeuticsVERA

$140K+64.7%

Ultragenyx PharmaceuticalRARE

$8M-11.1%

Agios PharmaceuticalsAGIO

$1.36M+6.7%

BridgeBio PharmaBBIO

$1.19M-7.6%

Kiniksa Pharmaceuticals International, plcKNSA

$468K+35.7%

Other financials

Income statement

See full

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Balance sheet

See full

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Cash flow

See full

Operating cash flow$32.6M+2,405%

Valuation

See full

Market cap$2.3B+78.5%

Enterprise value$2.34B+78.3%

P/E7.7×-24.6×

P/S7.7×+2.5×

Profitability

See full

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Returns & leverage

See full

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aurinia Pharmaceuticals's D&A?: Aurinia Pharmaceuticals (AUPH) reported D&A of $4.82M in Q1 2026.
How has Aurinia Pharmaceuticals's D&A changed year-over-year?: Aurinia Pharmaceuticals's D&A decreased by 0.8% year-over-year, from $4.86M to $4.82M.
What is the long-term trend for Aurinia Pharmaceuticals's D&A?: Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's D&A has grown at a 80.8% compound annual growth rate (CAGR), from $1.82M to $19.45M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.